List of Excipients in Branded Drug TELMISARTAN AND HYDROCHLORTHIAZIDE

« Back to Dashboard

Generic Drugs Containing TELMISARTAN AND HYDROCHLORTHIAZIDE

Company	Ingredient	NDC	Excipient
Torrent Pharmaceuticals Limited	telmisartan and hydrochlorthiazide	13668-159	FERRIC OXIDE YELLOW
Torrent Pharmaceuticals Limited	telmisartan and hydrochlorthiazide	13668-159	HYPROMELLOSE 2910
Torrent Pharmaceuticals Limited	telmisartan and hydrochlorthiazide	13668-159	LACTOSE MONOHYDRATE
Torrent Pharmaceuticals Limited	telmisartan and hydrochlorthiazide	13668-159	MANNITOL

What are the Most Frequently-Used Excipients in TELMISARTAN AND HYDROCHLORTHIAZIDE?

# Of NDCs	Excipient
1	FERRIC OXIDE YELLOW
1	HYPROMELLOSE 2910
1	LACTOSE MONOHYDRATE
1	MANNITOL

Telmisartan and Hydrochlorothiazide Excipient Strategy and Commercial Opportunities

Last updated: October 6, 2026

Telmisartan/hydrochlorothiazide is a mature fixed-dose antihypertensive combination with broad generic availability and limited conventional patent protection. The main formulation challenge is improving dissolution and content uniformity for two poorly soluble active ingredients while maintaining chemical stability, tablet robustness, low manufacturing cost, and acceptable patient tolerability. The strongest commercial opportunities are differentiated generic products, orally disintegrating or sprinkle-enabled presentations, low-cost global products, and formulations with improved dissolution or reduced excipient burden.

What is the formulation profile of telmisartan and hydrochlorothiazide?

Telmisartan/hydrochlorothiazide combines an angiotensin II receptor blocker with a thiazide diuretic. Approved strengths in the United States include 40 mg/12.5 mg, 80 mg/12.5 mg, and 80 mg/25 mg tablets.[1]

Attribute	Telmisartan	Hydrochlorothiazide
Drug class	Angiotensin II receptor blocker	Thiazide diuretic
Typical combination role	Primary blood-pressure reduction	Additive blood-pressure reduction
Aqueous solubility	Poor and pH-dependent	Low
Formulation concern	Dissolution, wetting, microenvironmental pH	Dissolution, content uniformity
Dose in combination	40 or 80 mg	12.5 or 25 mg
Primary dosage form	Immediate-release tablet	Immediate-release tablet
Commercial status	Mature generic market	Mature generic market

Telmisartan is a weakly acidic, poorly water-soluble compound. Its dissolution improves under alkaline conditions. Hydrochlorothiazide also has limited aqueous solubility, creating a dual-dissolution problem in a conventional immediate-release tablet.[2,3]

The combination does not require a modified-release system for its approved indication. The commercial objective is usually robust immediate release rather than prolonged delivery.

Which excipients are used in branded telmisartan/hydrochlorothiazide tablets?

The original Micardis HCT formulation used a solubilizing and alkaline excipient system that included meglumine, sodium hydroxide, sorbitol, povidone, lactose monohydrate, and magnesium stearate.[1]

Excipient	Primary formulation function	Strategic relevance
Meglumine	Alkalinizing agent and solubilizer	Supports telmisartan dissolution
Sodium hydroxide	pH adjustment and alkalinity	Creates a favorable microenvironment for telmisartan
Sorbitol	Filler and processing aid	Supports tablet mass and mouthfeel
Lactose monohydrate	Diluent	Low-cost tablet bulking agent
Povidone	Binder	Supports granule and tablet strength
Magnesium stearate	Lubricant	Controls ejection and tooling friction

The branded excipient system demonstrates that the formulation is not a simple physical blend of two active ingredients. Telmisartan requires pH management, while hydrochlorothiazide requires adequate wetting, dispersion, and dissolution. The excipient strategy must also control segregation because the two actives have different dose levels and particle characteristics.

How should excipients be selected for a generic formulation?

A generic formulation should begin with a target product profile centered on dissolution equivalence, impurity control, content uniformity, and scalable processing. The best excipient system will depend on whether the product is manufactured by direct compression, dry granulation, or wet granulation.

Alkalinizing and solubilizing excipients

Meglumine is the most recognizable enabling excipient for telmisartan. Other candidate approaches include sodium carbonate, potassium carbonate, bicarbonate systems, arginine, tromethamine, and controlled quantities of sodium hydroxide. Each option changes the tablet's pH microenvironment and may affect stability.

An alkaline excipient can improve telmisartan dissolution but can also create risks:

• Increased degradation under high-pH conditions.
• Greater sensitivity to moisture.
• Excipient incompatibility with hydrochlorothiazide or other formulation components.
• Variable dissolution if alkaline material is poorly distributed.
• Higher risk of batch-to-batch pH variation.

Meglumine is commercially attractive because it combines alkalinity with relatively good solid-state handling. It can also reduce the need for high levels of inorganic base. A formulation using meglumine may be easier to position as a direct generic alternative than a product relying on a novel pH-modifying system.

Fillers and compressibility agents

Lactose monohydrate is a conventional choice for low-cost tablets, but it is not the only option. Microcrystalline cellulose, mannitol, dibasic calcium phosphate, and spray-dried lactose can improve flow or tablet strength.

Microcrystalline cellulose is useful when direct compression is the preferred process. It improves compactibility and can help produce smaller tablets. Its use must be balanced against moisture sensitivity and tablet disintegration performance.

Mannitol is relevant for orally disintegrating or rapidly dispersible products because it has good mouthfeel and a cooling sensation. It is usually more expensive than lactose and may require a stronger binding strategy.

Dibasic calcium phosphate can improve flow and reduce hygroscopicity, but its density and compression behavior may complicate uniform distribution of low-dose hydrochlorothiazide.

Binders and disintegrants

Povidone, copovidone, hydroxypropyl cellulose, and pregelatinized starch are potential binders. Sodium starch glycolate, crospovidone, and croscarmellose sodium are common disintegrants.

The disintegrant is commercially important because excessive binder or lubricant can delay tablet breakup and reduce dissolution. Crospovidone may be useful where rapid wicking and low swelling are preferred. Croscarmellose sodium can provide strong disintegration but requires control of compression force and formulation moisture.

A two-stage granulation approach may improve content uniformity by separating the higher-dose telmisartan fraction from hydrochlorothiazide. That approach increases manufacturing complexity and may reduce the cost advantage of the product.

Lubricants and glidants

Magnesium stearate is standard, but its concentration and mixing time require control. Over-lubrication can create a hydrophobic tablet surface and slow dissolution. Sodium stearyl fumarate may be considered when faster dissolution or reduced hydrophobicity is needed, although it can change tooling behavior and cost.

Colloidal silicon dioxide can improve powder flow, particularly where direct compression is used. It should be evaluated for its effect on blend uniformity and electrostatic behavior.

What formulation strategy best addresses telmisartan dissolution?

The preferred approach is a controlled alkaline microenvironment combined with rapid tablet disintegration. Telmisartan should not simply be exposed to a large excess of base without stability testing. The formulation should demonstrate:

1. Rapid release in standard dissolution media.
2. Comparable release across pH conditions.
3. Controlled tablet microenvironmental pH.
4. Low levels of degradation products.
5. Stable assay and dissolution after accelerated storage.
6. Consistent performance across commercial-scale batches.

A practical development sequence is:

Development stage	Primary objective
Excipient screening	Identify solubilizer, filler, binder, and disintegrant combinations
Compatibility testing	Assess active-excipient degradation and physical interactions
Prototype tablets	Compare direct compression and granulation
Dissolution optimization	Establish pH-independent or robust release
Stability studies	Monitor assay, impurities, water uptake, hardness, and dissolution
Scale-up	Confirm blend uniformity, compression performance, and process capability

Solid-state characterization should include powder X-ray diffraction, differential scanning calorimetry, microscopy, particle-size analysis, and moisture sorption. These tests help determine whether processing causes polymorphic change, amorphization, agglomeration, or segregation.

What dosage forms and formulations are protected or commercially differentiated?

The conventional immediate-release tablet is highly commoditized. Differentiation requires a clear patient or manufacturing benefit.

Orally disintegrating tablets

An orally disintegrating tablet could target patients with dysphagia, elderly patients, and patients who have difficulty swallowing multiple antihypertensive tablets. The technical challenge is tablet size. An 80 mg telmisartan dose combined with 25 mg hydrochlorothiazide requires sufficient drug loading, and the alkaline solubilizer can increase tablet mass.

Potential excipients include mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and taste-masking agents. Telmisartan and hydrochlorothiazide are not inherently ideal for an uncoated oral product because taste and mouthfeel may limit acceptance.

Sprinkle or dispersible formulations

A multiparticulate or dispersible product could support administration to patients who cannot swallow tablets. The product would require validated stability after dispersion and clear instructions regarding food, water volume, and immediate administration.

The main barrier is regulatory and commercial rather than purely technical. The product must establish that the alternative administration method does not alter exposure or dose delivery.

Bilayer or compartmentalized tablets

A bilayer tablet could separate telmisartan from hydrochlorothiazide during processing and reduce direct-contact compatibility risks. It may also allow separate optimization of each active's dissolution environment.

The disadvantages are higher equipment costs, greater process complexity, and potential regulatory requirements to demonstrate consistent layer weight and interfacial integrity.

Fixed-dose combination with other antihypertensives

Telmisartan/hydrochlorothiazide can be incorporated into broader cardiovascular portfolios that include telmisartan/amlodipine, amlodipine/hydrochlorothiazide, or triple antihypertensive products. Each additional active increases tablet size, dissolution complexity, analytical burden, and regulatory risk.

When does telmisartan/hydrochlorothiazide lose exclusivity?

The principal U.S. composition and combination patent barriers for telmisartan and hydrochlorothiazide are historical rather than a major current barrier to generic entry. Micardis HCT was approved by the FDA in 2009, and multiple generic products have entered the market.[1,4]

Exclusivity category	Commercial assessment
Small-molecule composition patents	Historical protection; not a current barrier for standard generic entry
Fixed-dose combination patents	Historical protection; largely exhausted for commercial planning
Method-of-use patents	Limited practical value where the approved combination indication is established
Formulation patents	Relevant only if a specific branded or differentiated formulation remains enforceable
Pediatric exclusivity	Historical and no longer material to current entry planning
Regulatory exclusivity	No meaningful current barrier expected for standard ANDA products

Patent status must be assessed by jurisdiction and product-specific Orange Book records. A generic applicant should review the FDA Orange Book, listed patents, patent-use codes, court certifications, and any current litigation before filing.[4]

What is the Orange Book status and Paragraph IV risk?

A standard telmisartan/hydrochlorothiazide tablet is generally an ANDA opportunity rather than a 505(b)(2) opportunity. An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug, including strength, dosage form, route of administration, and labeling requirements.

Paragraph IV risk is most relevant when:

• A remaining patent is listed for the reference product.
• The generic applicant seeks approval before patent expiry.
• The proposed formulation relies on a non-infringement or invalidity position.
• A formulation patent covers a specific solubilizing or release technology.

For a mature combination with broad generic participation, the greater business risk is often price erosion and bioequivalence failure rather than patent litigation. A formulation with a novel delivery system may move into 505(b)(2) territory and create a new patent profile, but it also faces higher development cost and clinical or bridging requirements.

Which companies compete in the telmisartan/hydrochlorothiazide market?

Competition includes the original innovator and generic manufacturers marketing telmisartan/hydrochlorothiazide tablets across the United States, Europe, India, and other regulated markets. Generic competition is typically strongest in the standard strengths:

• 40 mg/12.5 mg
• 80 mg/12.5 mg
• 80 mg/25 mg

The competitive factors are manufacturing cost, supply reliability, product availability, wholesaler contracts, regulatory approvals, and the ability to offer multiple strengths. A company with an established hypertension portfolio can obtain commercial leverage by bundling this product with telmisartan monotherapy and other fixed-dose combinations.

What commercial opportunities exist for excipient-enabled products?

Low-cost global generic

The most accessible opportunity is a conventional immediate-release tablet using widely available excipients. The product should prioritize robust dissolution, simple manufacturing, and low packaging cost. This is suitable for high-volume markets but exposed to intense price competition.

Premium generic with improved dissolution

A formulation using optimized meglumine, carbonate buffering, particle engineering, or a co-processed excipient system could target markets where reliable dissolution and supply continuity have commercial value. The product would need comparative dissolution data and a defensible manufacturing advantage.

Patient-centric dosage form

An orally disintegrating or dispersible product could command a higher price if it demonstrates improved administration for dysphagia populations. The commercial opportunity is narrower than the standard tablet market and depends on reimbursement and prescriber adoption.

Regional licensing

Licensing opportunities may arise where one party owns a formulation platform and another has local registration, manufacturing, or distribution capability. The strongest structure is likely a regional supply or registration deal rather than a broad global license because the base product is already generic.

Manufacturing and intellectual-property barriers

Manufacturing barriers can still create competitive protection even after patent expiry. These include:

• A stable, reproducible alkaline microenvironment.
• Low-dose hydrochlorothiazide uniformity.
• Moisture-controlled processing.
• High-throughput compression without capping or sticking.
• Consistent dissolution after long-term storage.
• Specialized bilayer or multiparticulate equipment.
• Proprietary particle-size or co-processing technology.

These barriers are operational rather than absolute. They may support a formulation patent or trade-secret position, but the commercial value depends on whether the formulation produces a measurable clinical, regulatory, or manufacturing benefit.

What generic launch scenarios exist?

Launch scenario	Expected commercial profile	Main risk
Standard tablet, three strengths	Broadest market access	Rapid price erosion
Two-strength launch focused on 80/12.5 and 80/25 mg	Lower initial complexity	Reduced tender coverage
ODT or dispersible product	Premium differentiation	Larger development and regulatory burden
Bilayer tablet	Compatibility and process differentiation	Higher capital cost
Emerging-market product	Volume and registration opportunity	Pricing and supply-chain pressure
Portfolio bundle with telmisartan products	Cross-selling and contracting leverage	Limited standalone differentiation

Revenue exposure is most sensitive to generic entry count, payer contracting, tender wins, manufacturing cost, and supply availability. The product should be evaluated as part of a cardiovascular portfolio rather than as an isolated asset. A manufacturer with existing telmisartan, hydrochlorothiazide, or amlodipine registrations can reduce regulatory and commercial costs.

How strong is the patent estate for telmisartan/hydrochlorothiazide?

The estate is weak for a standard immediate-release generic product because the underlying small-molecule combination is mature and broadly commercialized. Patent strength is higher only for a genuinely differentiated formulation, such as:

• A defined alkaline-solubilizer ratio.
• A specific excipient architecture that produces superior dissolution.
• A bilayer or separated-active configuration.
• A novel dispersible or orally disintegrating dosage form.
• A manufacturing process that produces a distinct solid-state or particle-size profile.

A formulation patent should be supported by comparative data against conventional tablets. Claims limited to routine excipient substitution are vulnerable to obviousness challenges. Trade-secret protection may be more practical for process parameters, blending order, granulation endpoint, and moisture-control conditions.

Key Takeaways

• Telmisartan and hydrochlorothiazide both present dissolution challenges, making excipient selection central to product performance.
• Meglumine, sodium hydroxide, or another controlled alkaline system is important for telmisartan dissolution.
• Lactose, microcrystalline cellulose, mannitol, povidone, crospovidone, croscarmellose sodium, and magnesium stearate are practical formulation options.
• The standard immediate-release tablet is a mature generic opportunity with limited current patent barriers.
• The strongest commercial opportunities are low-cost global supply, premium dissolution performance, orally disintegrating products, dispersible products, and portfolio bundling.
• The primary risks are price erosion, dissolution variability, moisture-related degradation, blend segregation, and tablet-size constraints.
• A differentiated formulation needs comparative performance data and a defensible manufacturing or intellectual-property position.

FAQs

Can telmisartan and hydrochlorothiazide be formulated in one tablet?

Yes. The approved product is an immediate-release fixed-dose tablet containing telmisartan and hydrochlorothiazide. The formulation requires control of telmisartan's pH-dependent dissolution and hydrochlorothiazide's low solubility.[1]

Is meglumine necessary in a telmisartan/hydrochlorothiazide generic?

No. Meglumine is a proven solubilizing and alkalinizing option, but a generic may use another excipient system if it meets equivalence, stability, dissolution, and regulatory requirements.

Which excipient improves telmisartan solubility?

Alkaline excipients and solubilizers can improve telmisartan dissolution. Meglumine is used in the branded combination, while carbonate, bicarbonate, arginine, tromethamine, and controlled sodium hydroxide systems may be evaluated during development.

Is telmisartan/hydrochlorothiazide suitable for an orally disintegrating tablet?

Potentially, but tablet size, taste, drug loading, alkaline excipient levels, and dissolution must be controlled. An ODT would be a differentiated product rather than a simple generic substitution.

Does telmisartan/hydrochlorothiazide have biosimilar risk?

No. Telmisartan and hydrochlorothiazide are chemically synthesized small molecules. The relevant competitive pathway is generic ANDA approval, not biosimilar approval.

References

1. U.S. Food and Drug Administration. (2009). Micardis HCT prescribing information.
2. U.S. Food and Drug Administration. (2023). Inactive ingredient database.
3. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.